2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4712 Longitudinal trends in renal biomarkers of US patients with sickle cell nephropathy

Santosh L Saraf, MD, Janet H. Ford, MPH, PhD2, Jing Zhao, PhD3, Jungyoon Moon, MS4, Junlong Li, PhD5, Camryn Lieb, ScM6, Alexandra Z Sosinsky, MSc7, Allison Keshishian, MPH8, Mike Callaghan, MD9
1 University of Illinois Chicago, Chicago, Illinois, United States
2 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
3 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States
6 Genesis Research Group, Hoboken, New Jersey, United States
7 Genesis Research Group, Hoboken, New Jersey, United States
8 Genesis Research Group, Hoboken, New Jersey, United States
9 Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, United States

Introduction: Sickle cell nephropathy is a complication of sickle cell disease (SCD) present in up to 30% of patients and is characterized by albuminuria and declining estimated glomerular filtration rate (eGFR), contributing to substantial morbidity and early mortality. Elevated urine albumin-to-creatinine ratio (uACR) ≥100 mg/g predicts persistent albuminuria and is widely used as an early marker of chronic kidney disease. Estimated GFR is a measure of renal function, and declining eGFR has been independently associated with early mortality in patients with SCD. This study aimed to characterize longitudinal trends in uACR and eGFR among patients at risk of persistent albuminuria in a real-world patient population with sickle cell nephropathy in the United States (US).

Methods: This was a retrospective observational study using real-world data from the American Society of Hematology Research Collaborative Data Hub (study period: January 1, 2015, through March 31, 2025). Eligible patients were aged ≥18 years, had a physician-attested diagnosis of sickle cell anemia (ie, HbSS or HbS/β0-thalassemia), and had ≥2 uACR values ≥100 mg/g (≥1 week apart and within 24 months).  Patients were required to have ≥12 months of data prior to the index date and ≥6 months of follow-up data. The index date was defined as the earliest date with a confirmatory uACR ≥100 mg/g and all study eligibility criteria being met. Patients who received renal replacement therapy, gene therapy, bone marrow or stem cell transplant prior to or at the index date were excluded. The baseline period comprised 12 months prior to and including the index date. The follow-up period extended from 1 day after the index date until death, last contact, date of censoring (receipt of any procedure listed in the exclusion criteria above), or end of study period. Patient demographics and clinical characteristics at baseline were summarized descriptively. The change from baseline in eGFR and uACR at 1, 3, and 5 years post-index was reported. The rate of change in eGFR during follow-up was assessed using a mixed-effects model for repeated measures.

Results: The study included 287 patients. Median (interquartile range [IQR]) age at index was 35.0 years (28.0 to 45.0), and 56.8% were female. Most patients were Black or African-American (95.8%). Median (IQR) laboratory values at baseline were 8.5 g/dL (7.5 to 9.2) for hemoglobin (Hb), 2.6 mg/dL (1.8 to 4.1) for total bilirubin, and 409.7 U/L (303.3 to 546.2) for lactate dehydrogenase. During the baseline period, the mean (SD) annualized rate of vaso-occlusive crises was 3.8 (6.2). The most common treatments during the baseline period were hydroxyurea (59.9%) and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (43.9%). Median (IQR) duration of follow-up was 2.8 years (1.6 to 4.4).

At baseline, mean (SD) eGFR among 285 patients was 105.1 (35.1) mL/min/1.73m2. Mean (SD) change from baseline in eGFR was −4.6 (9.2) mL/min/1.73m2 at 1 year (n=225), −10.0 (17.2) mL/min/1.73m2 at 3 years (n=119), and −14.3 (18.3) mL/min/1.73m2 at 5 years (n=31). The mean rate of change in eGFR was −2.1 mL/min/1.73m2 per year (95% CI, −2.8 to −1.5). At baseline, mean (SD) uACR among 287 patients was 533.9 (788.5) mg/g. Mean (SD) change from baseline in uACR was variable across follow-up: −58.4 (558.5) mg/g at 1 year (n=194), 117.9 (921.9) mg/g at 3 years (n=91), and −191.6 (1273.1) mg/g at 5 years (n=23).

Conclusions: This study assessed longitudinal eGFR and uACR trends among US patients with sickle cell nephropathy in a real-world setting. While eGFR steadily declined over the follow-up period, uACR levels showed high intra-patient variability and varied considerably over the years. These findings suggest that albuminuria alone may not reliably reflect renal disease trajectory, whereas eGFR provides a more consistent measure of renal function deterioration. These observations are consistent with prior studies and suggest that eGFR and uACR may provide complementary information regarding renal disease progression in patients with sickle cell nephropathy.

Santosh L Saraf, MD: Novartis - Research Funding; Pfizer - Research Funding; Agios Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); BEAM Therapeutics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Chiesi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)